Therapy Detail

Therapy Name RX-5902
Synonym
Therapy Description

RX-5902 binds to and inhibits Ddx5, which in turn inhibits beta-catenin signaling, results in down-regulation of gene expression and tumor cell growth inhibition (PMID: 25649741).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
RX-5902 CTNNB1 Inhibitor 26 RX-5902 binds to and inhibits Ddx5, which in turn inhibits beta-catenin signaling, results in down-regulation of gene expression and tumor cell growth inhibition (PMID: 25649741).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable RX-5902 Phase I Actionable In a Phase I trial, RX-5902 treatment resulted in stable disease in 43% (15/35) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 258P; NCT02003092). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02003092 Phase I RX-5902 RX-5902 Treatment of Subjects With Solid Tumors Active, not recruiting